Investigation of an anti-BP180 immunoglobulin in an ex vivo organ culture skin model

Bullous pemphigoid (BP) is a subepidermal autoimmune blistering skin disease, classically presenting with severe pruritus, erythema, tense blisters and erosions. BP is mediated by autoantibodies targeting the hemidesmosomal proteins BP180 and BP230 at the dermal-epidermal junction, triggering an inflammatory response, including complement activation and the infiltration of inflammatory cells, such as polymorphonuclear leukocytes (PMNs). 

Treatment of BP is based on general immunosuppressants, including corticosteroids, methotrexate and azathioprine. Their long-term use is often limited by adverse effects, especially in the elderly, multimorbid patient population. Therefore, further research into targeted therapies, which may cause less severe side effects, is needed. Ex vivo human skin models offer an opportunity to identify therapeutic targets and test therapies in intact human tissue. 

Building on the human skin organ culture (HSOC) model established for pemphigus vulgaris in the Hundt lab, this project aims to establish an HSOC model for BP. First, we will test the binding of monoclonal anti-BP180 antibodies to human skin. Once binding is demonstrated, we will investigate whether these anti-BP180 antibodies induce split formation in the presence of PMNs. If successfully established, the model would be used to examine the ability of an anti-CD89 antibody to block this split formation as a potential targeted therapy.